|
Age, years
|
68.4 (60.1–72.9)
|
|
Male
|
67 (78.8%)
|
|
Smoking status
| |
|
Current smoker
|
1 (1.2%)
|
|
Former smoker
|
49 (57.6%)
|
|
Never smoker
|
35 (41.2%)
|
|
Comorbidities before SARS-CoV-2 infection
| |
|
Obesity
|
28 (32.9%)
|
|
Class I (BMI 30–34.9)
|
15 (53.6%)
|
|
Class II (BMI 35–39.9)
|
10 (35.7%)
|
|
Class III (BMI ≥ 40)
|
3 (10.7%)
|
|
Cardiovascular
| |
|
Ischemic heart disease
|
9 (10.6%)
|
|
Heart failure
|
1 (1.2%)
|
|
Atrial fibrillation
|
7 (8.2%)
|
|
Stroke
|
2 (2.4%)
|
|
Respiratory diseases
| |
|
COPD
|
7 (8.2%)
|
|
Asthma
|
6 (7.1%)
|
|
Sleep apnea
|
16 (18.8%)
|
|
Other cardiovascular risk factors
| |
|
Hypertension
|
44 (51.8%)
|
|
Diabetes
|
21 (24.7%)
|
|
Dyslipidemia
|
27 (31.8%)
|
|
Thromboembolic disease
| |
|
Deep vein thrombosis
|
4 (4.7%)
|
|
Pulmonary embolism
|
0 (0.0%)
|
|
Intensive care unit
| |
|
Length of stay (days)
|
17 (11.0–26.5)
|
|
Intubation
|
73 (85.9%)
|
|
Neuromuscular blocking agents (N = 72)a
|
71 (98.6%)
|
|
High flow oxygen therapyb
|
35 (41.2%)
|
|
Before intubation
|
14 (16.5%)
|
|
After intubation
|
29 (41.4%)
|
|
Non-invasive ventilationb
|
12 (14.1%)
|
|
Before intubation
|
1 (1.2%)
|
|
After intubation
|
10 (14.1%)
|
|
Prone position
|
62 (73.8%)
|
|
Pulmonary embolism
|
20 (23.5%)
|
|
Hospital stay
| |
|
Length of hospitalization (days)
|
45 (20–62)
|
|
In-hospital COVID-directed treatments
| |
|
Corticosteroids
|
36 (42.4%)
|
|
Remdisivir
|
5 (5.9%)
|
|
Lopinavir
|
9 (10.6%)
|
|
Ritonavir
|
10 (11.8%)
|
|
Hydroxychloroquine
|
54 (63.5%)
|
|
Azithromycin
|
45 (52.9%)
|
|
Others macrolides
|
55 (64.7%)
|
|
Rehabilitation post hospitalization
| |
|
Admission in rehabilitation units
|
57 (67.1%)
|
|
Return home with rehabilitation
|
11 (12.9%)
|
|
Return home without rehabilitation
|
17 (20.0%)
|
